详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Lu You[1] ; Xue Jianxin[2] ; Deng Tao[3] ; Zhou Xiaojuan[2] ; Yu Kun[3] ; Deng Lei[4] ; Huang Meijuan[2] ; Yi Xin[5] ; Liang Maozhi[6] ; Wang Yu[7] ; Shen Haige[7] ; Tong Ruizhan[2] ; Wang Wenbo[8] ; Li Li[2] ; Song Jin[5] ; Li Jing[5] ; Su Xiaoxing[9] ; Ding Zhenyu[2] ; Gong Youling[2] ; Zhu Jiang[2] ; Wang Yongsheng[2,6] ; Zou Bingwen[2] ; Zhang Yan[2] ; Li Yanying[2] ; Zhou Lin[2] ; Liu Yongmei[2] ; Yu Min[2] ; Wang Yuqi[5] ; Zhang Xuanwei[2] ; Yin Limei[2] ; Xia Xuefeng[5] ; Zeng Yong[3] ; Zhou Qiao[10] ; Ying Binwu[11] ; Chen Chong[12] ; Wei Yuquan[12] ; Li Weimin[13] ; Mok Tony[14] ;

机构： [1]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. radyoulu@hotmail.com. [2]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. [3]Chengdu MedGenCell, Co., Ltd, Chengdu, China. [4]Jacobi Medical Center, NYC Health Hospitals, Albert Einstein College of Medicine, New York, NY, USA. [5]Geneplus-Beijing Institute, Beijing, China. [6]Center of GCP, West China Hospital, Sichuan University, Chengdu, China. [7]ZenRhyme Consulting Service, Ltd, Shanghai, China. [8]National Research Center for Translational Medicine, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [9]Berry Oncology Co. Ltd, Fujian, China. [10]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China. [11]Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China. [12]State Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China. [13]Department of Respiratory and Critical Care Medicine and Frontier Science Center of Disease Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [14]State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China.

出处：

DOI：

ISSN：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区细胞生物学 1 区医学：研究与实验

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区细胞生物学 1 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. radyoulu@hotmail.com.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Publisher Correction: Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.

文献详情